NCT03855020 is a clinical trial of Plasma EBV DNA in Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University.

Who is sponsoring NCT03855020?

NCT03855020 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT03855020?

Interventions in NCT03855020: Plasma EBV DNA.

What condition does NCT03855020 study?

NCT03855020 studies Nasopharyngeal Carcinoma.

Is NCT03855020 still recruiting?

NCT03855020 is currently status unknown. Last updated 18 June 2023.

Last reviewed 2023-06-18 · How we verify

NCT03855020

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients

Status unknown Last updated 18 June 2023

What this trial tests

trial testing Plasma EBV DNA in Nasopharyngeal Carcinoma in 1,000 participants. Status unknown.

Timeline

9 May 2019

Primary endpoint
10 May 2022

1 May 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	9 May 2019
Primary completion	10 May 2022
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

Plasma EBV DNA

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important informations of disease screening, disease relapse, and risks classification. In this study, the investigators will explore the impact of serial plasma EBV DNA during chemotherapy and radiotherapy on initial tumor response and long-term survival in patients with non-metastatic nasopharyngeal carcinoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study.
Lv J, Xu LX, Li ZX, Lin L, et al · · 2024 · cited 39× · PMID 39059389 · DOI 10.1016/j.ccell.2024.07.001
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.
Lv J, Zheng DX, Liang JH, Zhang N, et al · · 2026 · cited 1× · PMID 41813900 · DOI 10.1038/s41586-026-10244-w
Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects.
Auger S, Mishra V, Singh A, Miao Y, et al · · 2024 · cited 1× · PMID 39867572 · DOI 10.20935/acadonco7456

Verify or expand the search:

Other trials of Plasma EBV DNA

Trials testing the same drug.

NCT03087695 — Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma · unknown

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03855020 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 18 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03855020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing